cytarabine has been researched along with incb-018424 in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Borchmann, P; Engert, A; Monsef, I; Rancea, M; Skoetz, N; Will, A | 1 |
| Boissel, N; Cluzeau, T; Devillier, R; Dombret, H; Kiladjian, JJ; Lengline, E; Raffoux, E; Rey, J; Robin, M; Ronchetti, AM; Sebert, M; Vey, N | 1 |
| Abdulkadyrov, K; Fominykh, M; Martynkevich, I; Polushkina, L; Shuvaev, V; Udaleva, V | 1 |
| Bosi, A; Coltro, G; Guglielmelli, P; Mannelli, F; Pacilli, A; Vannucchi, AM | 1 |
| Diepstra, A; Huls, G; Kibbelaar, R; Nijland, M; Seitz, A; van den Berg, A; van Meerten, T; Visser, L | 1 |
5 other study(ies) available for cytarabine and incb-018424
| Article | Year |
|---|---|
Sixteenth biannual report of the Cochrane Haematological Malignancies Group: focus on Non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Carmustine; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Etoposide; Hematologic Neoplasms; Humans; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Melphalan; Nitriles; Nitrogen Mustard Compounds; Prednisone; Primary Myelofibrosis; Pyrazines; Pyrazoles; Pyrimidines; Quality of Life; Randomized Controlled Trials as Topic; Rituximab; Vincristine | 2014 |
Combination therapy with ruxolitinib plus intensive treatment strategy is feasible in patients with blast-phase myeloproliferative neoplasms.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Feasibility Studies; Female; Humans; Idarubicin; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Male; Middle Aged; Nitriles; Pyrazoles; Pyrimidines; Treatment Outcome | 2016 |
The combination treatment regimen of ruxolitinib with low-dose mercaptopurine or cytarabine in frail patients with blast-phase myelofibrosis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Combined Modality Therapy; Cytarabine; Fatal Outcome; Female; Humans; Mercaptopurine; Middle Aged; Nitriles; Primary Myelofibrosis; Pyrazoles; Pyrimidines; Retreatment; Treatment Outcome | 2017 |
A life-threatening ruxolitinib discontinuation syndrome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Diagnosis, Differential; Disease Progression; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Janus Kinase 2; Leukemia, Myeloid, Acute; Middle Aged; Nitriles; Pneumonia; Protein Kinase Inhibitors; Pulmonary Embolism; Pyrazoles; Pyrimidines; Remission Induction; Respiratory Distress Syndrome; Substance Withdrawal Syndrome; Thrombocythemia, Essential; Tomography, X-Ray Computed | 2017 |
Combined PD-1 and JAK1/2 inhibition in refractory primary mediastinal B-cell lymphoma.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Brentuximab Vedotin; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunoconjugates; Janus Kinase 1; Janus Kinase 2; Lymphoma, B-Cell; Mediastinal Neoplasms; Molecular Targeted Therapy; Neoplasm Proteins; Nitriles; Prednisone; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Radiotherapy, Adjuvant; Remission Induction; Rituximab; Salvage Therapy; Vincristine | 2018 |